Avian influenza is an infection caused by avian (bird) influenza (flu) viruses. These influenza viruses occur naturally among birds. Wild birds worldwide carry the viruses in their intestines, but usually do not get sick from them. However, avian influenza is very contagious among birds and can make some domesticated birds, including chickens, ducks, and turkeys, very sick and kill them.
An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.
PURE Bioscience, creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its SDC-based hard surface disinfectant is effective against the 2009 H1N1 and is included on the list published by the U.S. Environmental Protection Agency (EPA) of antimicrobial products effective against the 2009 H1N1 flu strain based on their effectiveness against other influenza A virus strains.
The Wildlife Conservation Society will play a key role in a new international effort to monitor diseases that move between animals and people in order to prevent the next global pandemic.
In hopes of preventing the next global pandemic and a possible death toll into the millions, UC Davis today launches an unprecedented international effort to find and control diseases that move between wildlife and people.
The United States Agency for International Development (USAID) is launching an Emerging Pandemic Threats (EPT) program that builds on the successes of the Agency's long-standing programs in disease surveillance, training, and outbreak response, particularly those addressing avian and pandemic influenza.
Aethlon Medical, Inc. announced today that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced that Dr. David B. Weiner, Chairman of Inovio’s Scientific Advisory Board, highlighted advances in electroporation-delivered SynCon™ DNA vaccines compared to other leading vaccine technologies at the AIDS Vaccine 2009 Conference being held this week in Paris, France.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, and the HIV Vaccine Trials Network (HVTN) announced today the initiation of a phase I clinical study of Inovio’s PENNVAX-B preventive DNA vaccine delivered using its proprietary electroporation technology.
University of California, Davis, researchers studying the 2009 H1N1 influenza virus, formerly referred to as "swine flu," have identified a group of immunologically important sites on the virus that are also present in seasonal flu viruses that have been circulating for years. These molecular sites appear to result in some level of immunity to the new virus in people who were exposed to the earlier influenza viruses.
PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE’s revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.
The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
Avian influenza (H5N1), rabies, plague, Bovine Spongiform Encephalopathy (BSE), and more recently swine flu (H1N1) are all examples of diseases that have made the leap from animals to humans.
Theraclone Sciences, Inc., a Seattle-based biotechnology company, and Zenyaku Kogyo Co., Ltd., a pharmaceutical company based in Tokyo, today announced that they have entered into a multi-year research and development agreement.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus (SynConTM) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th.
Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th Edition. Marking 30 years since its initial publication, it remains the most respected reference source of its kind, and maintains its relevance in the face of the emergence of newly recognized infectious diseases, including new strains of the swine (H1N1) and avian influenza viruses.
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council. The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.